Table 3 |
||||
|
Univariate and multivariate analyses of gene-expression prognostic factors (as continuous variables) for locoregional recurrences |
||||
|
Gene expression by quantitative rt-PCR (continuous variables) |
Univariate analysis |
Multivariate analysis |
||
|
|
|
|||
|
HR (RR) [95% CI] |
P |
HR (RR) [95% CI] |
P |
|
|
|
||||
|
Estrogen receptor-α |
1.22 [0.90–1.66] |
0.15 |
||
|
Estrogen receptor-β |
0.61 [0.39–0.95] |
0.04 |
0.54 |
|
|
Progesterone receptor |
1.13 [0.88–1.45] |
0.32 |
||
|
HER1 |
0.65 [0.37–1.13] |
0.10 |
0.72 |
|
|
HER2 |
0.89 [0.64–1.25] |
0.49 |
||
|
HER3 |
1.06 [0.55–2.02] |
0.87 |
||
|
HER4 |
1.22 [0.91–1.63] |
0.14 |
||
|
MKI 67 |
0.89 [0.61–1.30] |
0.56 |
||
|
Cyclin E1 |
0.81 [0.48–1.36] |
0.43 |
||
|
Cyclin E2 |
0.75 [0.49–1.14] |
0.18 |
||
|
GATA 3 |
1.61 [0.95–2.73] |
0.04 |
1.49 [0.92–2.39] |
0.06 |
|
IGF1R |
1.41 [0.93–2.14] |
0.13 |
||
|
NCoR |
0.90 [0.38–2.15] |
0.82 |
||
|
NCoA3/AIB1 |
0.51 [0.21–1.22] |
0.14 |
||
|
CYP19 (aromatase) |
0.48 [0.28–0.80] |
0.003 |
0.49 [0.29–0.82] |
0.003 |
|
Skp2 |
0.52 [0.23–1.17] |
0.10 |
0.18 |
|
|
CAF-1 p150 |
1.00 [0.48–2.12] |
1.00 |
||
|
CAF-1 p60 |
1.00 [0.97–1.03] |
0.94 |
||
|
|
||||
|
RR = relative risk for locoregional recurrence calculated with the nonparametric Cox model; CI = confidence interval; HER = human epidermal receptor. Because of lack of prognostic values of the clinical variables in univariate analysis, none was entered in the multivariate analysis. |
||||
|
Bollet et al. Breast Cancer Research 2009 11:R54 doi:10.1186/bcr2343 |
||||
